A serological switching from anti-dsDNA to anti-Sm antibodies coincided with severe clinical manifestations of systemic lupus erythematosus (hemophagocytosis, profundus and psychosis).
Ishii
M
M
Muramoto
Y
Y
Kosaka
H
H
Ohshima
S
S
Mima
T
T
Katada
Y
Y
Hirohata
S
S
Saeki
Y
Y
D000284:Administration, Oral; D000974:Antibodies, Antinuclear / Q000097:blood* / Q000276:immunology; D000918:Antibody Specificity; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D001324:Autoantigens / Q000276:immunology*; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use; D004247:DNA / Q000276:immunology*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005334:Fever / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007262:Infusions, Intravenous; D015850:Interleukin-6 / Q000134:cerebrospinal fluid; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000276:immunology* / Q000523:psychology; D051359:Lymphohistiocytosis, Hemophagocytic / Q000209:etiology*; D008569:Memory Disorders / Q000209:etiology; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000209:etiology*; D017411:Ribonucleoproteins, Small Nuclear / Q000276:immunology*; D012867:Skin / Q000473:pathology; D055517:snRNP Core Proteins
D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D001324:Autoantigens; D007166:Immunosuppressive Agents; D015850:Interleukin-6; D017411:Ribonucleoproteins, Small Nuclear; D055517:snRNP Core Proteins; D016572:Cyclosporine; D004247:DNA; D011239:Prednisolone; D008775:Methylprednisolone